ALA-3000 vs BI 1569912

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

ALA-3000

Developed by Alar Pharmaceuticals

Phase 1 in Major Depressive Disordersmall molecule
Partial signal

NCT06965569 · Phase 1 · completed

This randomized, double-blind, placebo-controlled multiple-dose study gave subcutaneous ALA-3000 or placebo, with a standard oral antidepressant, to patients with treatment-resistant depression. All of its primary measures were safety and tolerability measures, which have no formal efficacy test, so there is no met or missed result. The company reports that side effects were mild to moderate and that no dissociation, sedation or psychosis-like symptoms were seen. Effects on depression scores were exploratory. The figures come from the company's press release.

Reported efficacy

Incidence of treatment-related adverse events (AEs) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal orthostatic blood pressure (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal heart rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal blood oxygen saturation (pulse oximetry) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal respiratory rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal body temperature (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal 12-lead electrocardiogram (ECG) parameters (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal hematologic findings (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal serum chemistry test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine cytologic findings (Baseline (prior to dosing) and the End of Study (Day 36) visit); Incidence and severity of dissociative symptoms assessed by Clinician Administered Dissociative States Scale (CADSS) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of treatment-emergent sedation assessed by Modified Observer's Assessment of Alertness/ Sedation (MOAA/S) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of potential withdrawal symptoms assessed by Physician Withdrawal Checklist; 20-item (PWC-20) (Two weeks after last investigational product administration and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of suicide ideation assessed by Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of four-item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination); Injection site tolerability based on injection site grading scale (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site pain visual analog scale (VAS) (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site evaluation for potential reactions and evidence of removal (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit): Primary, safety and tolerability (no formal efficacy test): treatment-related adverse events were mild to moderate in severity, and no dissociation, sedation or psychosis-like symptoms were observed. (not_applicable)

Result source: NCT06965569

BI 1569912

Developed by Boehringer Ingelheim

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT06280235 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.

Reported efficacy

Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) (missed)

Result source: NCT06558344

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALA-3000BI 1569912
MADRS, change (acute)—Not reported-12.3 vs -12−0.3 vs placebo20 mg · wk 6 · n 74NCT06280235
10 other results
  • -10 vs -10.3 20 mg · wk 6 · n 66 · Phase 2 · primary NCT06558344
  • -19.9 vs -19.3 20 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -11.9 vs -12 10 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -10.6 vs -10.3 10 mg · wk 6 · n 36 · Phase 2 · primary NCT06558344
  • -7.8 vs -12 5 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -13.6 vs -10.3 5 mg · wk 6 · n 30 · Phase 2 · primary NCT06558344
  • -16.8 vs -19.3 5 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -5.7 vs -6.4 20 mg · wk 1.142857 · n 74 · Phase 2 · secondary NCT06280235
  • -5.9 vs -6.4 10 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
  • -5.2 vs -6.4 5 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported34.8% vs 33.8%+1 vs placebo20 mg · wk 6 · n 66NCT06280235
5 other results
  • 15.5% vs 11.3% 20 mg · wk 1.142857 · n 71 · Phase 2 · secondary NCT06280235
  • 31.4% vs 33.8% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 10 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
  • 20.6% vs 33.8% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 5 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
MADRS remission—Not reported21.2% vs 19.7%+1.5 vs placebo20 mg · wk 6 · n 66NCT06280235
2 other results
  • 25.7% vs 19.7% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 8.8% vs 19.7% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ALA-3000
—Not reported
BI 1569912
-12.3 vs -12−0.3 vs placebo20 mg · wk 6 · n 74NCT06280235
10 other results
  • -10 vs -10.3 20 mg · wk 6 · n 66 · Phase 2 · primary NCT06558344
  • -19.9 vs -19.3 20 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -11.9 vs -12 10 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -10.6 vs -10.3 10 mg · wk 6 · n 36 · Phase 2 · primary NCT06558344
  • -7.8 vs -12 5 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -13.6 vs -10.3 5 mg · wk 6 · n 30 · Phase 2 · primary NCT06558344
  • -16.8 vs -19.3 5 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -5.7 vs -6.4 20 mg · wk 1.142857 · n 74 · Phase 2 · secondary NCT06280235
  • -5.9 vs -6.4 10 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
  • -5.2 vs -6.4 5 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235

CGI-S, change (acute)

ALA-3000
—Not reported
BI 1569912
—Not reported

MADRS response

ALA-3000
—Not reported
BI 1569912
34.8% vs 33.8%+1 vs placebo20 mg · wk 6 · n 66NCT06280235
5 other results
  • 15.5% vs 11.3% 20 mg · wk 1.142857 · n 71 · Phase 2 · secondary NCT06280235
  • 31.4% vs 33.8% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 10 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
  • 20.6% vs 33.8% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 5 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235

MADRS remission

ALA-3000
—Not reported
BI 1569912
21.2% vs 19.7%+1.5 vs placebo20 mg · wk 6 · n 66NCT06280235
2 other results
  • 25.7% vs 19.7% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 8.8% vs 19.7% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235

Relapse (% of patients)

ALA-3000
—Not reported
BI 1569912
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALA-3000: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ALA-3000: 0 of 4 rows · BI 1569912: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBI 1569912
Dropout rate
9.6%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
7.3%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
12.5%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
9.6%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
14.6%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
17.1%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5%20 mg
NCT04937829 · Phase 1
15%5 mg
NCT04937829 · Phase 1
Discontinued due to AEs
2.4%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
4.9%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2.7%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
4.9%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—20 mg
NCT04937829 · Phase 1
—5 mg
NCT04937829 · Phase 1
Serious AEs
1.2%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
2.4%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
2.4%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%20 mg
NCT04937829 · Phase 1
0%5 mg
NCT04937829 · Phase 1
Most frequent reported AEs
20 mga
dizziness 8.4% (placebo 2.5%)
headache 8.4% (placebo 6.3%)
nasopharyngitis 4.8% (placebo 3.8%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
10 mg
headache 4.9% (placebo 6.3%)
upper respiratory tract infection 2.4% (placebo 6.3%)
dizziness 0% (placebo 2.5%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5 mg
headache 7.5% (placebo 6.3%)
nasopharyngitis 7.5% (placebo 3.8%)
upper respiratory tract infection 5% (placebo 6.3%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20 mg
headache 12.3% (placebo 7.9%)
nasopharyngitis 8.2% (placebo 3.9%)
diarrhoea 2.7% (placebo 1.3%)
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
10 mg
headache 9.8% (placebo 7.9%)
diarrhoea 4.9% (placebo 1.3%)
nasopharyngitis 4.9% (placebo 3.9%)
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5 mg
headache 14.3% (placebo 7.9%)
diarrhoea 5.7% (placebo 1.3%)
upper respiratory tract infection 5.7% (placebo 1.3%)
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20 mg
decreased appetite 5% (placebo 5.3%)
blood pressure increased 0% (placebo 0%)
constipation 0% (placebo 0%)
NCT04937829 · Phase 1
5 mg
blood pressure increased 10% (placebo 0%)
constipation 10% (placebo 0%)
headache 5% (placebo 5.3%)
NCT04937829 · Phase 1

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BI 1569912

MADRS -12.3 vs -12 placebo score @ 6wk20 mg
absolute change · score
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 10 more results
-5.7 vs -6.4 placebo score @ 1.142857wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-10 vs -10.3 placebo score @ 6wk20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
-19.9 vs -19.3 placebo score @ 1wk20 mg
NCT04937829 · Phase 1
-11.9 vs -12 placebo score @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-5.9 vs -6.4 placebo score @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-10.6 vs -10.3 placebo score @ 6wk10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-7.8 vs -12 placebo score @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-5.2 vs -6.4 placebo score @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-13.6 vs -10.3 placebo score @ 6wk5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-16.8 vs -19.3 placebo score @ 1wk5 mg
NCT04937829 · Phase 1
MADRS 15.5% (n=71) vs 11.3% (n=71) placebo @ 1.142857wk20 mg
responder rate · % of participants
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 5 more results
34.8% (n=66) vs 33.8% (n=71) placebo @ 6wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
11.1% (n=36) vs 11.3% (n=71) placebo @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
31.4% (n=35) vs 33.8% (n=71) placebo @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
11.1% (n=36) vs 11.3% (n=71) placebo @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20.6% (n=34) vs 33.8% (n=71) placebo @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
MADRS Remission 21.2% (n=66) vs 19.7% (n=71) placebo @ 6wk20 mg
responder rate · % of participants
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
25.7% (n=35) vs 19.7% (n=71) placebo @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8.8% (n=34) vs 19.7% (n=71) placebo @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
SMDDS -7.1 vs -7.6 placebo score @ 1.142857wk20 mg
absolute change · score
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 5 more results
-11.1 vs -10.4 placebo score @ 4wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-6.5 vs -7.6 placebo score @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.8 vs -10.4 placebo score @ 4wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-7.4 vs -7.6 placebo score @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.3 vs -10.4 placebo score @ 4wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALA-3000's landscape · BI 1569912's landscape